The FMHR traders and Stephanie Link of TIAA Global Asset Management, take their positions on stocks in earnings news, including Procter & Gamble's turnaround story. » Read More
It was not clear from the FDA report which antibiotics were used on various animals, why and in what volume. The FDA in 2013 released voluntary guidelines for drug makers and agricultural companies to phase out antibiotic use as a growth enhancer in livestock. "Sales does not equal use and use is not the same thing as resistance," said Ron Phillips, spokesman for the...
Dec 4- Eli Lilly& Co said on Friday it scrapped development of an experimental diabetes treatment that had raised concerns of liver problems. Nearly 12 in 1000 Americans are diagnosed with diabetes every year, according to the Centers for Disease Control and Prevention. Eli Lilly's shares closed at $83.06 on Thursday.
Dec 4- Eli Lilly& Co said it stopped developing its experimental diabetes treatment after discussions with regulatory authorities and external experts.
The "Halftime Report" traders give their top trades of the show.
Nov 24- The U.S. Food and Drug Administration said it had approved Eli Lilly& Co's Portrazza, in combination with two forms of chemotherapy, to treat patients with a type of lung cancer. The FDA's approval on Tuesday comes about four months after an advisory panel to the agency recommended the drug be cleared for sale along with the warnings. Eli Lilly's shares were...
Nov 24- The U.S. Food and Drug Administration on Tuesday approved Eli Lilly& Co's cancer treatment, Portrazza, in combination with two forms of chemotherapy to treat patients with advanced squamous non-small cell lung cancer.
Jim Cramer says this week was the most amazing transformation he has ever seen before. But can the bull continue to dance?
LONDON, Nov 18- Pearson boss John Fallon faces a daunting task to arrest the decline of the world's biggest education publisher as it battles growing political and economic strife. Fallon has endured a rough ride since he took over in 2013, with a string of profit warnings marking his tenure, in an abrupt end to the steady growth enjoyed by his predecessor...
NEW YORK, Nov 17- Healthcare companies that can either contain costs or develop medications to treat rare diseases, known as orphan drugs, will be the most likely to outperform in the coming year, said John Fraunces, whose Turner Medical Sciences Long/Short fund is among the top performing healthcare funds over the last 5 years. He is shorting AbbVie Inc, for...
About 1 in 5 Medicare dollars is spent on this disease that affects over 5 million Americans. Yet not enough is being done to find a cure.
The American Heart Association is holding its annual scientific sessions in Orlando, Florida from Nov 7 to 11, at which the latest clinical trials and research in heart care are being presented for thousands of cardiologists and researchers, including a large government-sponsored study on the benefits of more intensive blood pressure lowering in patients...
ORLANDO, Nov 9- Eli Lilly's new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday. The 3- year trial of more than 7,000 patients caused a sensation in September,...
U.S. stock index futures pointed to a sharply higher open on Thursday.
Some of the names on the move ahead of the open.
U.S. stock futures were higher this morning, with the market trying to avoid its first three-session losing streak of October.
Three Dow components and dozens of other companies will report earnings Thursday morning.
The "Halftime Report" traders give their top trades.
So far the earnings season has been lackluster, and some high-profile warnings have already given investors pause.
Jim Cramer arms investors with the inside mindset of how hedge funds and mutual funds will play this market slowdown.
U.S. stocks closed mildly higher Monday in low volume trade as investors readied for the first major earnings reports due Tuesday.